连续流左心室辅助装置患者的出血:获得性冯维勒布兰德病还是抗血栓治疗?
研究比较植入连续流左心室辅助装置(LVAD)后出血与未出血患者的冯维勒布兰德因子(vWf)降解程度,并分析抗血栓方案与出血的关系。53例患者中25例发生原发性出血(47%),均在使用华法林和阿司匹林期间。停用阿司匹林后仅3例出血复发。作者认为阿司匹林在获得性vW病背景下显著促成出血事件,停用可显著减少出血复发。
要点
- 53例LVAD患者中25例发生原发性出血(47%),全部发生于使用华法林和阿司匹林期间。
- 植入后vWf抗原和vWf胶原结合均显著下降,病理性vWf:CB/vWf:Ag比值(<0.7)患者比例随时间从26%升至74%。
- 停用阿司匹林后仅3例出血复发,作者认为阿司匹林在获得性vW病背景下显著促成出血。
核心结论
- 阿司匹林在获得性vW病背景下显著促成出血事件,停用阿司匹林可显著减少出血复发。
研究设计与样本
- 比较植入连续流LVAD后出血与未出血患者的vWf降解程度,测量时间点为植入前、短期(t1:<3个月)和长期(t2:>12个月)随访。
- 共纳入53例患者,中位随访324(226-468)天。
- 患者出院时使用华法林(国际标准化比值:2-2.5)和阿司匹林,首次出血事件后停用阿司匹林。
- 分析原发性出血事件及出血复发与患者特异性vWf谱和抗血栓方案的相关性。
主要发现
- 记录25例原发性出血事件(占患者47%),所有原发性事件均发生于使用华法林和阿司匹林的患者。
- 植入后vWf:Ag和vWf:CB均显著下降(P=0.0003和P<0.0001)。
- 病理性vWf:CB/vWf:Ag比值(<0.7)患者比例随时间进展:植入前26%、t1为58%、t2为74%(P<0.0001)。
- 出血者t2时大vWf多聚体活性显著低于未出血者:vWf:CB为61(36-115)vs 100(68-121),P=0.04;vWf:CB/vWf:Ag比值为0.36(0.26-0.61)vs 0.58(0.33-0.96),P=0.04。
- 停用阿司匹林后仅3例患者出血复发。
关键数值与推荐
- 病理性vWf:CB/vWf:Ag比值定义为<0.7。
- 华法林目标国际标准化比值为2-2.5。
临床怎么用
- 作者认为阿司匹林在获得性vW病背景下显著促成出血事件,停用阿司匹林可显著减少出血复发。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the competing pro-haemorrhagic contribution of acquired von Willebrand (vW) disease and antithrombotic therapy in patients implanted with continuous-flow left ventricular assist devices (LVADs). METHODS: We compared the extent of vW factor (vWf) degradation [vWf antigen (vWf:Ag)] and a decrease of functional activity of large vWf multimers [vWf collagen binding (vWf:CB)] in LVAD patients who did and did not suffer from bleeding. Data were measured pre-implant, at short-term (t1: <3 months) and long-term (t2: >12 months) follow-up. The occurrence of primary bleeding events, as well as bleeding recurrence, was correlated with patient-specific vWf profile and antithrombotic regimen. Indeed, patients were discharged on warfarin (international normalized ratio: 2-2.5) and aspirin, with the latter withhold after a first bleeding episode. RESULTS: Fifty-three patients were enrolled. The median follow-up was 324 (226-468) days. We recorded 25 primary bleeding events (47% of patients). All primary events occurred in patients on warfarin and aspirin. Both vWf:Ag and vWf:CB decreased significantly post-implant (P = 0.0003 and P < 0.0001), and patients showing pathological vWf:CB/vWf:Ag ratio (<0.7) increased progressively over the time of support (pre-implant = 26%, t1 = 58%, t2 = 74%; P < 0.0001). Of note, activity of large vWf multimers of bleeders was significantly lower at t2 with respect to non-bleeders (vWf:CB: 61 (36-115) vs 100 (68-121), P = 0.04; vWf:CB/vWf:Ag ratio: 0.36 (0.26-0.61) vs 0.58 (0.33-0.96), P = 0.04). Despite these marked differences in the vWf profile, following aspirin discontinuation only 3 patients had bleeding recurrence. CONCLUSIONS: Aspirin contributes significantly to haemorrhagic events in the background of acquired vW disease; its discontinuation significantly reduces bleeding recurrence. CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/ct2/show/NCT03255928; ClinicalTrials.gov Identifier: NCT03255928.
引用
- Consolo F, Marasi A, Della Valle P, et al. Bleeding in patients with continuous-flow left ventricular assist devices: acquired von Willebrand disease or antithrombotics? Eur J Cardiothorac Surg. 2022. PMID: 34718493. doi:10.1093/ejcts/ezab474
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。